Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 326 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hemoglobin Clear all

Conditions: Type 2 Diabetes Mellitus
Interventions: denagliptin (GW823093); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 57
States / cities: Tallassee, Alabama • Phoenix, Arizona • Tucson, Arizona + 52 more

Conditions: Diabetes Mellitus
Interventions: Alternate site blood glucose testing; Procedure
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sickle Cell Disease (SCD)
Interventions: crizanlizumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 12
States / cities: Orange, Florida • Tampa, Florida • Atlanta, Georgia + 9 more

Conditions: Physician Workflow, Resource Utilization
Interventions: OPA; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: Not listed
Enrollment: 384 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Myeloid Neoplasm
Interventions: Activity Tracking, Biospecimen Collection, Cognitive Assessment, Electronic Health Record Review, Packed Red Blood Cell Transfusion, Quality-of-Life Assessment; Other · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Type 2 Diabetes
Interventions: MOSAIC, Print Materials; Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 547 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Birmingham, Alabama • Nashville, Tennessee

Conditions: Anemia, Chronic Kidney Disease
Interventions: AKB-6548, Placebo; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years to 82 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 47
States / cities: Glendale, Arizona • Tucson, Arizona • Azusa, California + 44 more

Conditions: Pre-Diabetes
Interventions: Functional Ingredient Group, Control Ingredient Group; Dietary Supplement
Lead sponsor: University of Manitoba; Other
Eligibility: 21 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Anemia in Pregnancy
Interventions: Masimo spot hemoglobin non-invasive monitor; Device
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Anaemia
Interventions: Daprodustat, Darbepoetin alfa, Placebo, Iron Therapy; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 3,872 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 161
States / cities: Andalusia, Alabama • Birmingham, Alabama • Huntsville, Alabama + 128 more

Conditions: Diabetes Mellitus
Interventions: Live diabetes coaching program; Behavioral
Lead sponsor: Welkin Health; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Type 2 Diabetes
Interventions: vitamin D3, cholecalciferol, Inactive comparator; Dietary Supplement
Lead sponsor: Augusta University; Other
Eligibility: 19 Years to 60 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Trauma
Interventions: Radical-7 Pulse CO-Oximeter and sensor; Device
Lead sponsor: Masimo Corporation; Industry
Eligibility: 16 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Anaemia
Interventions: GSK1278863, rhEPO; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 42
States / cities: Paragould, Arizona • Tempe, Arizona • Pine Bluff, Arkansas + 34 more

Conditions: Low Back Pain
Interventions: Tissuelink device; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Sickle Cell Disease, Thalassemia
Interventions: Etavopivat tablets; Drug
Lead sponsor: Forma Therapeutics, Inc.; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 14
States / cities: Cerritos, California • Los Angeles, California • Oakland, California + 9 more

Conditions: CKD Anemia in Stable Dialysis Patients
Interventions: Epoetin Alfa, Roxadustat; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years and older
Enrollment: 741 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 74
States / cities: Phoenix, Arizona • Pine Bluff, Arkansas • Chula Vista, California + 58 more

Conditions: Type 2 Diabetes
Interventions: Medically tailored meals; Dietary Supplement
Lead sponsor: Mayo Clinic; Other
Eligibility: 25 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Jacksonville, Florida

Conditions: Sickle Cell Disease
Interventions: Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a; Biological
Lead sponsor: David Williams; Other
Eligibility: 13 Years to 55 Years
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus, Type 2
Interventions: vildagliptin, thiazolidinedione (TZD); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 2,665 participants
Timeline: Started 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Diabetes Mellitus, Vitamin D Deficiency
Interventions: Vitamin D; Dietary Supplement
Lead sponsor: Ascension Health; Industry
Eligibility: 34 Years to 69 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Flint, Michigan

Conditions: Diabetes Mellitus, Impaired Fasting Glucose, Prediabetes
Interventions: Re-infusion of biotin labeled cells, Diabetes education/diabetes medication adjustment; Biological · Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 85 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Anaemia, Aspergillosis, Allergic Bronchopulmonary
Interventions: Daprodustat, rhEPO, Placebo, Iron therapy; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 2,964 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 126
States / cities: Huntsville, Alabama • Pine Bluff, Arkansas • Anaheim, California + 103 more

Conditions: Sickle Cell Disease, Sickle B+ Thalassemia, Sickle Beta Zero Thalassemia, Sickle Cell Hemoglobin C
Interventions: HU-Go app; Other
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 12 Years to 25 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Study Of Denagliptin In Subjects With Type 2 Diabetes Mellitus (T2DM)

Self Monitoring of Blood Glucose With Finger Tip vs. Alternate Site Sampling: Effect on Long Term Glycemic Control

Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)

Evaluating a Our Practice Advisory (OPA) to Optimize Hemoglobin A1c (A1c) and Thyroid-Stimulating Hormone (TSH) Test Orders

Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia

MObile Support Adapted to Individual Contexts

20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

Designer Functional Foods on Parameters of Metabolic and Vascular in Prediabetes

Non-invasive Spot Hemoglobin Measurement in the Outpatient Obstetric Clinic

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

Evaluating the Impact of a Technologically-Enhanced Personal Coaching Program on Hemoglobin A1c in Type 2 Diabetics

The Effect of Vitamin D Supplementation on Glucose Metabolism in Non-Diabetic African American Adults

Evaluation of Non-Invasive Hemoglobin in Trauma Patients

4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease

TissueLink Study During Multi-Level Spine Surgery

A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease

Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis

Effect of Medically-tailored Meal Delivery Service on Changes in Hemoglobin A1c (HbA1c) in Patients With Diabetes

Expanded Access Protocol for Gene Therapy Utilizing shmiR Lentivirus Vector to Induce Fetal Hemoglobin in Sickle Cell Disease

Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone

Effect of Vitamin D Supplementation on Hemoglobin A1c

Effect of Red Blood Cell Survival on a Commonly Used Diabetes Lab Test-HbA1c

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)

Adherence to HU and HRQOL in Patients With Sickle Cell Disease: An Intervention Study Using HU-Go App